UK Ophthalmic Drugs Market

ID: MRFR/Pharma/43556-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
UK Ophthalmic Drugs Market Research Report By Dosage Form (Eye Drops, Eye Ointments, Eye Solutions, Gels, Capsules Tablets, Others), By Product Type (Prescription Drug, OTC Drug), By Drug Class (Antibiotics, Anti-Inflammatory, Anti-Glaucoma, Others), By Indication (Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, Others) and By Distribution Channels (Hospital pharmacies, Drug stores, Online pharmacies, Others) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Ophthalmic Drugs Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)5.73%
2024 Market Size$ 2.06 Billion
2025 Market Size$ 2.19 Billion
2035 Market Size$ 3.8 Billion

Key Players

Novartis
Roche
Allergan
Bausch Health
Santen Pharmaceutical
Hoya Corporation
Trends
  • Technological Advancements in Drug Delivery
  • Rise of Personalized Medicine
  • Regulatory Adaptations
Opportunities
  • Growing Awareness of Eye Health
  • Government Initiatives and Funding
  • Increasing Prevalence of Eye Disorders
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Anti-Inflammatory
      2. 4.1.2 Antibiotic
      3. 4.1.3 Antiglaucoma
      4. 4.1.4 Lubricants
      5. 4.1.5 Antiviral
    2. 4.2 Healthcare, BY Formulation (USD Billion)
      1. 4.2.1 Eye Drops
      2. 4.2.2 Ointments
      3. 4.2.3 Gels
      4. 4.2.4 Injectables
      5. 4.2.5 Implants
    3. 4.3 Healthcare, BY Route of Administration (USD Billion)
      1. 4.3.1 Topical
      2. 4.3.2 Systemic
      3. 4.3.3 Intravitreal
      4. 4.3.4 Subconjunctival
      5. 4.3.5 Periocular
    4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
      1. 4.4.1 Glaucoma
      2. 4.4.2 Infection
      3. 4.4.3 Dry Eye Syndrome
      4. 4.4.4 Allergic Conjunctivitis
      5. 4.4.5 Retinal Disorders
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Allergan (IE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bausch Health (CA)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Santen Pharmaceutical (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Hoya Corporation (JP)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Johnson & Johnson (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY APPLICATION
    3. 6.3 UK MARKET ANALYSIS BY FORMULATION
    4. 6.4 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 UK MARKET ANALYSIS BY THERAPEUTIC AREA
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    14. 6.14 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion)
    16. 6.16 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    18. 6.18 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
      2. 7.2.2 BY FORMULATION, 2026-2035 (USD Billion)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
      4. 7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Ophthalmic Drugs Market Segmentation

UK Ophthalmic Drugs Market By Application (USD Billion, 2026-2035)

  • Anti-Inflammatory
  • Antibiotic
  • Antiglaucoma
  • Lubricants
  • Antiviral

UK Ophthalmic Drugs Market By Formulation (USD Billion, 2026-2035)

  • Eye Drops
  • Ointments
  • Gels
  • Injectables
  • Implants

UK Ophthalmic Drugs Market By Route of Administration (USD Billion, 2026-2035)

  • Topical
  • Systemic
  • Intravitreal
  • Subconjunctival
  • Periocular

UK Ophthalmic Drugs Market By Therapeutic Area (USD Billion, 2026-2035)

  • Glaucoma
  • Infection
  • Dry Eye Syndrome
  • Allergic Conjunctivitis
  • Retinal Disorders

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035